Case Report
Copyright ©The Author(s) 2022.
World J Clin Cases. Jun 16, 2022; 10(17): 5916-5922
Published online Jun 16, 2022. doi: 10.12998/wjcc.v10.i17.5916
Table 1 Studies of epidermal growth factor receptor-tyrosine kinase inhibitors response for delE709_T710insD
Ref.
Patient No.
Gender
Age (yr)
Smoking
Stage
Histologic type
TKI used/line
Response
PFS (m)
OS (m)
Wu et al[7], 20111F61NoIVADGefitinib/NASD5.122.7
2M65YesIVADGefitinib/NAPD0.911.1
Ackerman et al[9], 20123F88NoIVADErlotinib/1stPR6NA
Kobayashi et al[19], 20154M63NAIVADErlotinib/3rdSDNANA
Afatinib/4th PRNA
Wu et al[6], 20165F57NoIVADGefitinib/NAPD0.624.1
6M79YesIVADGefitinib/NASD6.26.2
7M68YesIVADGefitinib/NAPD2.329.5
Klughammer et al[10], 20168F50NoIII/IVNSCLCErlotinib/2ndPD1.31.7
Ibrahim et al[13], 20179F52NoIVADAfatinib/1stPRNANA
An et al[14], 201910M56NoIVADAfatinib/2ndPR11More than 21
Iwamoto et al[15], 201911F56NoIVADAfatinib/6thPR7NA
D’Haene et al[16], 201912F57NoIIIADAfatinib/2ndPR1236
Martin et al[11], 201913M60NoIVADErlotinib/NAPD13
Isaksson et al[12], 202014NANANAIVNAErlotinib/1stPD8NA
Sousa et al[8], 202015F66YesIVADGefitinib/1stPD324
16F46YesIIADErlotinib/2ndPD426
17F57NoIVADErlotinib/2ndPD318
Wei et al[17], 202118F70NoIINSCLCAfatinib/1stPR23On going
Jelli et al[18], 202119F57NoIVADAfatinib/1stCR17 (On going)17 (On going)
Xu et al, 2021 (this case)20F56NoIVADDacomitinib/2ndPR7On going